This trial tested whether implantable cardioverter-defibrillators (ICDs) reduce sudden cardiac death (SCD) or hemodynamically significant ventricular arrhythmia (HSVA) in patients with a left ventricular ejection fraction (LVEF) of 36% to 50% and myocardial scar.
This randomized clinical trial compares the effects of an implantable cardioverter-defibrillator vs an implantable loop recorder on sudden cardiac death risk or hemodynamically significant ventricular arrhythmia in patients with a left ventricular ejection fraction of 36% to 50% and a myocardial…
The implantable cardioverter-defibrillator (ICD) remains a cornerstone therapy for the prevention of sudden cardiac death. Randomized clinical trials have demonstrated a survival benefit with ICDs for primary prevention in patients with a left ventricular ejection fraction (LVEF) of 35% or less…
This JAMA Insights discusses various aspects of primary aldosteronism, such as its epidemiology, diagnosis and screening, and treatment, including effective medication management.
This cohort study examines the clinical, histologic, and prognostic features of metabolic dysfunction–associated steatotic liver disease and noninvasive tests for advanced fibrosis in lean individuals vs individuals with overweight or obesity.
Evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD) relies on the “visible proxy” of body size. This is understandable: excess adiposity, associated with insulin resistance, type 2 diabetes, and cardiometabolic dysfunction, is a major driver of the global MASLD epidemic.…
This Perspective urges multimodal management of obesity that extends beyond pharmacological treatment to screening, early management, and intensive behavioral therapy across the life course.
This Perspective discusses the actions needed to improve accessibility of glucagon-like peptide-1 (GLP-1) receptor agonists, especially in low- and middle-income countries, after their addition to the World Health Organization’s (WHO) Model List of Essential Medicines.
This cross-sectional study examines glucagon-like peptide-1 (GLP-1) receptor agonist initiation rates among postpartum women with commercial insurance in the US.